FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1255146572> ?p ?o ?g. }

• W1255146572 abstract "Chronic fatigue syndrome (CFS) is an illness that occurs worldwide. Over the years the syndrome has had various labels, ranging from the Victorian one of neurasthenia to the putative neurological diagnosis of benign myalgic encephalomyelitis (Acheson 1959). A working case definition was published by the Centers for Disease Control in 1988 (Holmes et al) and revised in 1994 (Fukuda et al). In the initial studies of patients with CFS, impaired activation of hypothalamic-pituitary-adrenal (HPA) axis (Demitrack et al 1991) and monoaminergic dysfunction (Demitrack et al 1992; Bakheit et al 1992) was reported. Dynamic neuroendocrine challenge tests provide one of the only methods for examining neurotransmitter function in vivo in humans (Checkley 1980). In the following studies these tests were used to examine different neurotransmitter systems and their influence on the functional activity of the HP A, hypothalamic-somatotroph and hypothalamic-prolactin axes. In the first study, serotonin (5-HT) function in CFS was evaluated using the specific 5-HT1A receptor agonist, buspirone. It was found that prolactin responses to this agent were augmented in patients with chronic fatigue syndrome compared to healthy controls. This finding does not support the view that CFS is a form of depressive disorder because in depression, prolactin responses to this 5-HT1A agonist (Bakheit et al 1992) and to d-fenfluramine (Cleare et al 1995) are blunted reflecting decreased 5-HT neurotransmission. The study is therefore of importance in suggesting that CFS unlike depression, may be associated with increased 5-HT function. The second study is based on the hypothesis that abnormalities in the HPA-axis (Demitrack et al 1991) arise from a disturbance in serotinergic neurotransmission. ACTH and cortisol responses to the selective 5-HT1A receptor agonist ipsapirone were examined; no differences in baseline ACTH and cortisol levels were found but in CFS, there was significant attenuation of ACTH release. Study 3 was designed to demonstrate the functional integrity of the hypothalamic-somatotroph axis and its interaction with the HPA-axis. Growth hormone (GH) responses to dexamethasone were examined in two phases, before and after the administration of metyrapone, an inhibitor of 11-beta hydroxylation, given to block steroid synthesis and upregulate brain steroid receptors. Blunted responses were recorded in each phase in patients with CFS and depression compared to healthy controls. It is concluded that the abnormality found is compatible with a decrease response and/or a lack of plasticity in cerebral glucocorticoid receptors. In study 4, noradrenergic function was examined by measuring GH responses to the monoamine reuptake inhibitor, desipramine; blunted responses were found in patients with CFS, compared to healthy individuals. It is concluded that the attenuated response is due to decreased sensitivity of the alpha2-postsynaptic adrenoceptor, secondary to a hyperadrenergic state, indicating that central noradrenergic function is decreased in patients with CFS. In study 5, growth hormone responses to anticholinesterase, pyridostigmine were examined: augmented responses were found in the CFS group, compared to the healthy individuals. This enhanced response reflects increased sensitivity of acetylcholine (ACh) neurotransmitter function in CFS. In studies 6 & 7, growth hormone responses to the dopamine agonist, bromocriptine, and to the GABA(B) agonist, baclofen, were measured in order to assess dopamine (DA) and GABA neurotransmitter function. The responses in patients with CFS were the same as in the healthy controls. It is concluded that dopamine (DA) and GABA neurotransmitter systems are not involved in the pathophysiology of CFS. In summary, the neuroendocrine investigations revealed positive findings of a) upregulation of 5-HT receptors with increased 5-HT function, b) impaired activation of the FTPA-axis to serotonin input, c) cerebral steroid receptor resistance and d) reciprocal dysfunction in noradrenaline (NE) and acetylcholine (ACh)-mediated endocrine responses. These findings suggest that CFS is an organic illness with definite neuroendocrine abnormalities. Some of the neuroendocrine abnormalities are similar to those reported in depression, suggesting the reason why these two illnesses may share common symptoms." @default.
• W1255146572 created "2016-06-24" @default.
• W1255146572 creator A5061931413 @default.
• W1255146572 date "1996-01-01" @default.
• W1255146572 modified "2023-09-28" @default.
• W1255146572 title "Neuroendocrine alterations in chronic fatigue syndrome" @default.
• W1255146572 cites W114039586 @default.
• W1255146572 cites W114949761 @default.
• W1255146572 cites W119582027 @default.
• W1255146572 cites W132108989 @default.
• W1255146572 cites W1481283116 @default.
• W1255146572 cites W1527593681 @default.
• W1255146572 cites W1534046497 @default.
• W1255146572 cites W1538919177 @default.
• W1255146572 cites W1563823233 @default.
• W1255146572 cites W176436028 @default.
• W1255146572 cites W1824216224 @default.
• W1255146572 cites W1833464065 @default.
• W1255146572 cites W1852740264 @default.
• W1255146572 cites W1858496028 @default.
• W1255146572 cites W1958847481 @default.
• W1255146572 cites W1966092598 @default.
• W1255146572 cites W1967007542 @default.
• W1255146572 cites W1968644334 @default.
• W1255146572 cites W1969031814 @default.
• W1255146572 cites W1971383287 @default.
• W1255146572 cites W1971625462 @default.
• W1255146572 cites W1971922927 @default.
• W1255146572 cites W1973302984 @default.
• W1255146572 cites W1975574477 @default.
• W1255146572 cites W1978372813 @default.
• W1255146572 cites W1980552031 @default.
• W1255146572 cites W1980800874 @default.
• W1255146572 cites W1982660773 @default.
• W1255146572 cites W1984303719 @default.
• W1255146572 cites W1984520396 @default.
• W1255146572 cites W1985792537 @default.
• W1255146572 cites W1986593598 @default.
• W1255146572 cites W1988010405 @default.
• W1255146572 cites W1989153302 @default.
• W1255146572 cites W1992026501 @default.
• W1255146572 cites W1993591393 @default.
• W1255146572 cites W1994037589 @default.
• W1255146572 cites W1995455468 @default.
• W1255146572 cites W1997460348 @default.
• W1255146572 cites W1997993870 @default.
• W1255146572 cites W1998763370 @default.
• W1255146572 cites W1998891861 @default.
• W1255146572 cites W1999407262 @default.
• W1255146572 cites W1999445315 @default.
• W1255146572 cites W2000994164 @default.
• W1255146572 cites W2001778399 @default.
• W1255146572 cites W2003967896 @default.
• W1255146572 cites W2004306126 @default.
• W1255146572 cites W2005884135 @default.
• W1255146572 cites W2006193334 @default.
• W1255146572 cites W2006835766 @default.
• W1255146572 cites W2007554763 @default.
• W1255146572 cites W2008216659 @default.
• W1255146572 cites W2008412976 @default.
• W1255146572 cites W2009075951 @default.
• W1255146572 cites W2009291774 @default.
• W1255146572 cites W2009639016 @default.
• W1255146572 cites W2010156206 @default.
• W1255146572 cites W2011935206 @default.
• W1255146572 cites W2012257183 @default.
• W1255146572 cites W2017540100 @default.
• W1255146572 cites W2019464419 @default.
• W1255146572 cites W2019894839 @default.
• W1255146572 cites W2020060674 @default.
• W1255146572 cites W2021817325 @default.
• W1255146572 cites W2022516521 @default.
• W1255146572 cites W2023916700 @default.
• W1255146572 cites W2024608942 @default.
• W1255146572 cites W2028136556 @default.
• W1255146572 cites W2029139790 @default.
• W1255146572 cites W2029748309 @default.
• W1255146572 cites W2029866425 @default.
• W1255146572 cites W2030988675 @default.
• W1255146572 cites W2031667205 @default.
• W1255146572 cites W2032599422 @default.
• W1255146572 cites W2032901458 @default.
• W1255146572 cites W2033088418 @default.
• W1255146572 cites W2034122751 @default.
• W1255146572 cites W2035652846 @default.
• W1255146572 cites W2036110474 @default.
• W1255146572 cites W2036393776 @default.
• W1255146572 cites W2036589524 @default.
• W1255146572 cites W2036789254 @default.
• W1255146572 cites W2040120263 @default.
• W1255146572 cites W2041642361 @default.
• W1255146572 cites W2043948759 @default.
• W1255146572 cites W2044453795 @default.
• W1255146572 cites W2047635131 @default.
• W1255146572 cites W2047862779 @default.
• W1255146572 cites W2048509416 @default.
• W1255146572 cites W2049396259 @default.
• W1255146572 cites W2051715358 @default.
• W1255146572 cites W2052283730 @default.
• W1255146572 cites W2052613238 @default.

• next